In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Akiko Yamashita, Nobuhiro Hidaka, Ryo Yamamoto, Soichiro Nakayama, Jun Sasahara, Keisuke Ishii, Nobuaki Mitsuda

研究成果: Contribution to journalArticle査読

8 被引用数 (Scopus)

抄録

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

本文言語英語
ページ(範囲)451-457
ページ数7
ジャーナルJournal of Clinical Ultrasound
43
7
DOI
出版ステータス出版済み - 9 2015

All Science Journal Classification (ASJC) codes

  • 放射線学、核医学およびイメージング

フィンガープリント

「In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル